Two new studies evaluate agents for treating ulcerative colitis
In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a variety of measures. ...
Sep 27, 2019
0
7